Andere Sprachen Omega Therapeutics, Inc.

Aktien

A3CWDR

US68217N1054

OMGA

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
2.27 ^USD	-3.40%		-5.42%	-24.58%

16.04.	Omega Therapeutics, Inc. ernennt Barbara Chan zum Principal Accounting Officer mit Wirkung zum 31. Mai 2024	CI
09.04.	Omega Therapeutics, Inc. präsentiert neue präklinische Daten auf dem AACR 2024, die das Potenzial der epigenomischen Präzisionskontrolle belegen	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting	23.04.
Omega Therapeutics CFO Joshua Reed to Depart	16.04.
Omega Therapeutics, Inc. Announces Executive Changes, Effective as of May 31, 2024	16.04.
Omega Therapeutics, Inc. Designates Barbara Chan as Principal Accounting Officer, Effective as of May 31, 2024	16.04.
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09.04.
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control	09.04.
Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control	09.04.
Omega Therapeutics Cuts Headcount by 35%, Narrows Q4 Loss	28.03.
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update	28.03.
Omega Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28.03.
Omega Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.03.
North American Morning Briefing : Stocks Set for -2-	28.03.
North American Morning Briefing : Investors -2-	21.03.
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024	06.03.
Omega Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Novel Therapeutic for Obesity Management	05.01.
Sector Update: Health Care Stocks Stronger Late Afternoon	04.01.
Top Midday Gainers	04.01.
Novo Nordisk Collaborates With Omega Therapeutics, Cellarity on Cardiometabolic Diseases Research	04.01.
Top Premarket Gainers	04.01.
Wegovy maker Novo Nordisk enters research tie-ups with US biotech firms	04.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Omega Therapeutics, Inc.

Aktien

A3CWDR

US68217N1054

OMGA

Andere Sprachen

Filter